Moreover, since it prevents the growth of aggressive Myc+Bcl2+ murine lymphoma cells that express BTLA and lack HVEM in vivo, CAR-T cells that restore loss of HVEM are a promising therapeutic strategy [78]. The gene discussed is TNFRSF14; the disease is lymphoma.